Liposomal MTP-PE.
Gano
J B
JB
Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Kleinerman
E S
ES
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004337:Drug Carriers; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D008081:Liposomes; D008545:Melanoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D010714:Phosphatidylethanolamines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology
D000970:Antineoplastic Agents; D004337:Drug Carriers; D007155:Immunologic Factors; D008081:Liposomes; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine